Juno Therapeutics Inc (NASDAQ:JUNO) – Equities research analysts at Wedbush issued their FY2022 earnings estimates for Juno Therapeutics in a research report issued on Wednesday. Wedbush analyst D. Nierengarten anticipates that the biopharmaceutical company will post earnings of ($0.71) per share for the year. Wedbush currently has a “Neutral” rating on the stock.
Several other equities analysts have also weighed in on the stock. Raymond James Financial lifted their target price on shares of Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Citigroup restated a “buy” rating and set a $59.00 target price on shares of Juno Therapeutics in a report on Tuesday, October 31st. Wells Fargo & Co lowered shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 12th. Finally, SunTrust Banks upgraded shares of Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 2nd. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $47.26.
Juno Therapeutics (JUNO) traded down $3.56 during trading hours on Friday, hitting $67.81. 5,220,193 shares of the company traded hands, compared to its average volume of 3,350,000. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. The firm has a market cap of $7,740.00, a price-to-earnings ratio of -20.00 and a beta of 2.32. Juno Therapeutics has a 1-year low of $19.07 and a 1-year high of $74.35.
Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business’s quarterly revenue was up 115.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.57) EPS.
Several institutional investors and hedge funds have recently added to or reduced their stakes in JUNO. Bank of New York Mellon Corp increased its position in shares of Juno Therapeutics by 7.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 281,858 shares of the biopharmaceutical company’s stock worth $8,425,000 after purchasing an additional 19,057 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Juno Therapeutics by 80.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 113,124 shares of the biopharmaceutical company’s stock worth $3,382,000 after purchasing an additional 50,378 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Juno Therapeutics by 15.4% in the 2nd quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after purchasing an additional 9,890 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Juno Therapeutics by 9.0% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 188,481 shares of the biopharmaceutical company’s stock worth $5,634,000 after purchasing an additional 15,491 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Juno Therapeutics by 2.6% in the 2nd quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after purchasing an additional 110,503 shares during the last quarter. 69.94% of the stock is owned by institutional investors.
In other news, EVP Robert Azelby sold 6,666 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the completion of the sale, the executive vice president now owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Steve Harr sold 8,750 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the completion of the sale, the chief financial officer now directly owns 772,082 shares of the company’s stock, valued at approximately $34,558,390.32. The disclosure for this sale can be found here. Insiders have sold a total of 365,337 shares of company stock worth $17,540,499 in the last ninety days. 15.08% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “FY2022 Earnings Estimate for Juno Therapeutics Inc (JUNO) Issued By Wedbush” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/19/fy2022-earnings-estimate-for-juno-therapeutics-inc-juno-issued-by-wedbush.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.